Incorporation of health technologies: The importance of drug treatment of primary headaches in the Brazilian unified health system

André Luiz Godoi; Erlene Roberta Ribeiro dos Santos; Juliana Ramos Andrade

doi:10.48208/HeadacheMed.2022.27

Authors

André Luiz Godoi Fundação Faculdade Regional de Medicina de Sao José do Rio Preto https://orcid.org/0000-0003-0390-3670
Erlene Roberta Ribeiro dos Santos Universidade Federal de Pernambuco, Vitoria de Santo Antao, Pernambuco, Brazil https://orcid.org/0000-0003-3334-3408
Juliana Ramos Andrade Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil https://orcid.org/0000-0002-5445-8872

DOI:

https://doi.org/10.48208/HeadacheMed.2022.27

Keywords:

Drugs, Headaches, Public health, Tecnology, Migraine

Abstract

Incorporation of health technologies: The importance of drug treatment of primary headaches in the Brazilian unified health system

Downloads

Download data is not yet available.

References

Schmidt MI, Duncan BB, e Silva GA, Menezes AM, Monteiro CA, Barreto SM, . . . Menezes PR. Chronic non-communicable diseases in Brazil: burden and current challenges. The Lancet 2011;377(9781):1949-1961 Doi: 10.1016/s0140-6736(11)60135-9 DOI: https://doi.org/10.1016/S0140-6736(11)60135-9

Souza MNP, Cohen JM, Piha T, Ribalov R, Lengil T, van der Laan A, . . . Lee LK. Burden of migraine in Brazil: A cross‐sectional real‐world study. Headache: The Journal of Head and Face Pain 2022;62(10):1302-1311 Doi: 10.1111/head.14413 DOI: https://doi.org/10.1111/head.14413

Peres MFP, Queiroz LP, Rocha-Filho PS, Sarmento EM, Katsarava Z and Steiner TJ. Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys. The Journal of Headache and Pain 2019;20(1):Doi: 10.1186/s10194-019-1036-6

Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA and Zukerman E. A Nationwide Population-Based Study of Migraine in Brazil. Cephalalgia 2009;29(6):642-649 Doi: 10.1111/j.1468-2982.2008.01782.x

De Souza Silva M, Esther da Silva Alves G, Thiago de Lima Silva J, Flaudiano Bem Leite A and Roberta Ribeiro dos Santos E. Internações por enxaqueca. Jornal Memorial da Medicina 2020;1(2):57-65 Doi: 10.37085/jmmv1.n2.2019.pp.57-65 DOI: https://doi.org/10.37085/jmmv1.n2.2019.pp.57-65

Krymchantowski A, Jevoux C, Silva-Neto RP and Krymchantowski AG. Migraine Treatment in Emergency Departments of Brazil: A Retrospective Study of 2 Regions. Headache 2020;60(10):2413-2420 Doi: 10.1111/head.13999 DOI: https://doi.org/10.1111/head.13999

Peres MFP, Queiroz LP, Rocha-Filho PS, Sarmento EM, Katsarava Z and Steiner TJ. Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys. J Headache Pain 2019;20(1):85 Doi: 10.1186/s10194-019-1036-6 DOI: https://doi.org/10.1186/s10194-019-1036-6

Queiroz LP, Peres MF, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA and Zukerman E. A nationwide population-based study of migraine in Brazil. Cephalalgia 2009;29(6):642-649 Doi: 10.1111/j.1468-2982.2008.01782.x DOI: https://doi.org/10.1111/j.1468-2982.2008.01782.x

Domingues RB, Aquino CC, Santos JG, da Silva AL and Kuster GW. Prevalence and impact of headache and migraine among Pomeranians in Espirito Santo, Brazil. Arq Neuropsiquiatr 2006;64(4):954-957 Doi: 10.1590/s0004-282x2006000600013 DOI: https://doi.org/10.1590/S0004-282X2006000600013

Raffaelli E. Migraine awareness, treatment, and education in Brazil. Cephalalgia 1998;18 Suppl 22(67; discussion 67-68 Doi: 10.1177/0333102498018s2213 DOI: https://doi.org/10.1177/0333102498018S2213

Nichols V, Pearce G, Ellard DR, Evans S, Haywood K, Norman C, . . . team C. Patient and public involvement in a UK National Institute for Health Research Programme Grant for Applied Research: experiences from the Chronic Headache Education and Self-management Study (CHESS). Prim Health Care Res Dev 2021;22:e72 Doi: 10.1017/S1463423621000670 DOI: https://doi.org/10.1017/S1463423621000670

Charleston Lt and Evans RW. Public policy and headache: observations of health care policy in the US congress from a legislative fellow's perspective. Headache 2013;53(5):827-830 Doi: 10.1111/head.12098 DOI: https://doi.org/10.1111/head.12098

Steiner TJ. Headache in the world: public health and research priorities. Expert Rev Pharmacoecon Outcomes Res 2013;13(1):51-57 Doi: 10.1586/erp.12.78 DOI: https://doi.org/10.1586/erp.12.78

Ziegler DK. Headache. Public health problem. Neurol Clin 1990;8(4):781-791 DOI: https://doi.org/10.1016/S0733-8619(18)30316-5

Kowacs F, Roesler CAdP, Piovesan ÉJ, Sarmento EM, Campos HCd, Maciel Jr JA, . . . Jurno ME. Consensus of the Brazilian Headache Society on the treatment of chronic migraine. Arquivos de Neuro-Psiquiatria 2019;77(7):509-520 Doi: 10.1590/0004-282x20190078 DOI: https://doi.org/10.1590/0004-282x20190078

Relação Nacional de Medicamentos Essenciais Rename 2022 [recurso eletrônico] / Ministério da Saúde, Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde, Departamento de Assistência Farmacêutica e Insumos Estratégicos. – Brasília : Ministério da Saúde, 2022. 181 p. : il.

Silberstein SD and Edvinsson L. Is CGRP a marker for chronic migraine? Neurology 2013;81(14):1184-1185 Doi: 10.1212/WNL.0b013e3182a6cc33 DOI: https://doi.org/10.1212/WNL.0b013e3182a6cc33

Aggarwal M, Puri V and Puri S. Serotonin and CGRP in migraine. Ann Neurosci 2012;19(2):88-94 Doi: 10.5214/ans.0972.7531.12190210 DOI: https://doi.org/10.5214/ans.0972.7531.12190210

Salvatore CA and Kane SA. CGRP receptor antagonists: toward a novel migraine therapy. Curr Pharm Biotechnol 2011;12(10):1671-1680 Doi: 10.2174/138920111798357401 DOI: https://doi.org/10.2174/138920111798357401

Tvedskov JF, Tfelt-Hansen P, Petersen KA, Jensen LT and Olesen J. CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine. Cephalalgia 2010;30(11):1346-1353 Doi: 10.1177/0333102410363491 DOI: https://doi.org/10.1177/0333102410363491

Ho TW, Edvinsson L and Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6(10):573-582 Doi: 10.1038/nrneurol.2010.127 DOI: https://doi.org/10.1038/nrneurol.2010.127

Schelstraete C and Paemeleire K. CGRP antagonists: hope for a new era in acute migraine treatment. Acta Neurol Belg 2009;109(4):252-261

Tfelt-Hansen P and Ashina M. CGRP in migraine. J Headache Pain 2009;10(5):385; author reply 387-388 Doi: 10.1007/s10194-009-0139-x DOI: https://doi.org/10.1007/s10194-009-0141-3

Edvinsson L. CGRP blockers in migraine therapy: where do they act? Br J Pharmacol 2008;155(7):967-969 Doi: 10.1038/bjp.2008.346 DOI: https://doi.org/10.1038/bjp.2008.346

Durham PL. CGRP receptor antagonists: a new choice for acute treatment of migraine? Curr Opin Investig Drugs 2004;5(7):731-735

Brain SD, Poyner DR and Hill RG. CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine? Trends Pharmacol Sci 2002;23(2):51-53 Doi: 10.1016/s0165-6147(02)01945-4 DOI: https://doi.org/10.1016/S0165-6147(02)01945-4

Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin Investig Drugs 2001;2(9):1261-1268

Autunno M, Messina C, Blandino A and Rodolico C. Hypnic headache responsive to low-dose topiramate: a case report. Headache 2008;48(2):292-294 Doi: 10.1111/j.1526-4610.2007.01000.x DOI: https://doi.org/10.1111/j.1526-4610.2007.01000.x

Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ and Group T-M-S. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27(7):814-823 Doi: 10.1111/j.1468-2982.2007.01326.x DOI: https://doi.org/10.1111/j.1468-2982.2007.01326.x

Palacio E, Rodero L and Pascual J. Topiramate-responsive headache due to idiopathic intracranial hypertension in Behcet syndrome. Headache 2004;44(5):436-437 Doi: 10.1111/j.1526-4610.2004.04095.x DOI: https://doi.org/10.1111/j.1526-4610.2004.04095.x

Leone M, Dodick D, Rigamonti A, D'Amico D, Grazzi L, Mea E and Bussone G. Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia 2003;23(10):1001-1002 Doi: 10.1046/j.1468-2982.2003.00665.x DOI: https://doi.org/10.1046/j.1468-2982.2003.00665.x

McGeeney BE. Topiramate in the treatment of cluster headache. Curr Pain Headache Rep 2003;7(2):135-138 Doi: 10.1007/s11916-003-0023-3 DOI: https://doi.org/10.1007/s11916-003-0023-3

Rapoport AM, Bigal ME, Tepper SJ and Sheftell FD. Treatment of cluster headache with topiramate: effects and side-effects in five patients. Cephalalgia 2003;23(1):69-70; author reply 70 Doi: 10.1046/j.1468-2982.2003.00481_1.x DOI: https://doi.org/10.1046/j.1468-2982.2003.00481_1.x

Aschehoug I, Bratbak DF and Tronvik EA. Long-Term Outcome of Patients With Intractable Chronic Cluster Headache Treated With Injection of Onabotulinum Toxin A Toward the Sphenopalatine Ganglion - An Observational Study. Headache 2018;58(10):1519-1529 Doi: 10.1111/head.13398 DOI: https://doi.org/10.1111/head.13398

Russo M, Manzoni GC, Taga A, Genovese A, Veronesi L, Pasquarella C, . . . Torelli P. The use of onabotulinum toxin A (Botox((R))) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. Neurol Sci 2016;37(7):1127-1131 Doi: 10.1007/s10072-016-2568-z DOI: https://doi.org/10.1007/s10072-016-2568-z

Yerry JA, Kuehn D and Finkel AG. Onabotulinum toxin a for the treatment of headache in service members with a history of mild traumatic brain injury: a cohort study. Headache 2015;55(3):395-406 Doi: 10.1111/head.12495 DOI: https://doi.org/10.1111/head.12495

Incorporation of health technologies: The importance of drug treatment of primary headaches in the Brazilian unified health system

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

How to Cite

Issue

Section

License

Most read articles by the same author(s)

Language

Make a Submission

Style